You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing Real-time Interaction and Motion Tracking in Immersive Virtual Reality for Telerehabilitation

    SBC: Move LLC            Topic: 102

    Abstract Unceasing breakthroughs in technology will shape future healthcare diagnosis, treatment, and delivery. Telerehabilitation delivers rehabilitative healthcare remotely to overcome spatial, temporal and economic barriers. Effectiveness of telerehabilitation has been seen for patients with orthopedic and traumatic injuries, degenerative central nervous system disorders, and cardiovascular dis ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. A Deep Learning Model to Improve Pathologist Interpretation of Donor Kidney Biopsies

    SBC: NEWVENTUREIQ LLC            Topic: 400

    ABSTRACT More people die every year from kidney disease than breast or prostate cancer. Kidney transplantation is life-saving, yet the donor organ shortage and high organ discard rate contributes to 13 deaths daily among patients awaiting transplant. The decision to use or discard a donor kidney relies heavily on microscopic quantitation of chronic damage by pathologists. The current standard of c ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Anti-inflammatory and Anti-diabetic Therapy for Metabolic Syndrome

    SBC: APT THERAPEUTICS, INC.            Topic: 200

    Principal Investigator/Program Director (Last, First, Middle: Chen, Ridong AbstractMetabolic syndrome (MetS), affects more than 50 million people in the US alone. The current standard of care embodies polypharmacological therapies that are mostly directed at controlling individual risk factors of MetS (e.g. lipid altering agents, anti-hypertensives, and insulin sensitizers), but most of these trea ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Developing novel immunoassays specific for thyroid stimulating and TSHblocking autoantibodies

    SBC: MEDIOMICS, LLC            Topic: 200

    AbstractGraves’ disease (GD) is the most common cause of hyperthyroidism, accounting for 60 to 80 percent of more than 250 million cases of hyperthyroidism globally. Quantification of TSHR stimulating autoantibodies (TSAbs) can provide important guidance for the diagnosis and management of the disease, including predicting relapse or remission after initial anti-thyroid drug treatment or disease ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Novel insulin-sensitizing NASH/diabetes drugs.

    SBC: BIOIO, LLC            Topic: 300

    Obesity is associated with an increased risk of a number of chronic and progressive diseases and obesity- related metabolic diseases constitute a significant public health burden. The increased likelihood of developing insulin resistance and diabetes is probably the most commonly recognized risk of being obese. In addition, obesity is also associated with accumulation of lipid in the liver parench ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a New Treatment for Diabetic Wounds

    SBC: NUTRIWYO LLC            Topic: NIDDK

    Abstract: Non-healing wounds affect ~25% of people with diabetes and represent a primary cause of amputation of lower limbs, which is an enormous clinical problem and a substantial economic burden. Given the lack of approved agents that effectively aid in the healing of diabetic wounds, a major need exists for developing novel pharmacological agents for treating diabetic wounds. Chronic diabetic w ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Ciclopirox Prodrug as a Novel Systemic Treatment for High-Risk Non-Muscle Invasive Bladder Cancer

    SBC: CICLOMED LLC            Topic: 102

    Project Summary The American Cancer Society estimates ~80,470 patients will be diagnosed with bladder cancer (BCa) and ~17,670 will die of the disease in the US this year (www.cancer.org). BCa exists as two diseases, non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). Approaches to treating NMIBC and MIBC, as well as treatment outcomes, are quite different. Despit ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Therapy System for Atrial Fibrillation

    SBC: CARDIALEN, INC.            Topic: NHLBI

    Project Summary/Abstract We propose the development and evaluation of a novel implantable low-energy device, using an innovative low-energy approach, to achieve tolerable, nearly pain free treatment of atrial fibrillation. Atrial fibrillation (AF) is a global epidemic. Approximately 33.5 million individuals are affected worldwide and close to 5 million new cases occur each year costing the US heal ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Visual biofeedback to reduce head motion during MRI scans

    SBC: TURING MEDICAL TECHNOLOGIES INC            Topic: 101

    Project Abstract/Summary The goal of this STTR application is to deliver a brain MRI technology that feeds back head motion measurements derived from our Framewise Integrated Real-Time MRI Monitoring (FIRMM) to MRI scan participants in order to reduce head motion via behavioral training. Because MRI scanning produces high- resolution images and does not expose patients to radiation, it has become ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis

    SBC: Senseion Therapeutics, Inc.            Topic: 300

    Non-alcoholic fatty liver (NAFL) and its progression to advanced stage non-alcoholic steatohepatitis (NASH) is a growing health concern, with 83.1 million Americans affected in 2015, and projections to reach 100.9 million by 2030. Metabolic syndrome and Type 2 diabetes (T2D) are considered significant pathophysiological contributors to NAFL-NASH progression, therefore, novel therapeutic strategies ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government